Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DARATUMUMAB Cause Oxygen saturation decreased? 200 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 200 reports of Oxygen saturation decreased have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.7% of all adverse event reports for DARATUMUMAB.

200
Reports of Oxygen saturation decreased with DARATUMUMAB
0.7%
of all DARATUMUMAB reports
26
Deaths
84
Hospitalizations

How Dangerous Is Oxygen saturation decreased From DARATUMUMAB?

Of the 200 reports, 26 (13.0%) resulted in death, 84 (42.0%) required hospitalization, and 18 (9.0%) were considered life-threatening.

Is Oxygen saturation decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 200 reports have been filed with the FAERS database.

What Other Side Effects Does DARATUMUMAB Cause?

Plasma cell myeloma (2,980) Infusion related reaction (2,557) Off label use (2,494) Pneumonia (1,450) Neutropenia (1,351) Drug ineffective (1,110) Thrombocytopenia (1,089) Death (1,088) Pyrexia (1,032) Dyspnoea (996)

What Other Drugs Cause Oxygen saturation decreased?

TREPROSTINIL (3,865) RITUXIMAB (3,139) AMBRISENTAN (1,791) MACITENTAN (1,666) TOCILIZUMAB (1,501) METHOTREXATE (971) PREDNISONE (880) PACLITAXEL (833) ADALIMUMAB (813) SELEXIPAG (810)

Which DARATUMUMAB Alternatives Have Lower Oxygen saturation decreased Risk?

DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ DARATUMUMAB vs DARBEPOETIN ALFA DARATUMUMAB vs DARIDOREXANT DARATUMUMAB vs DARIFENACIN HYDROBROMIDE DARATUMUMAB vs DAROLUTAMIDE

Related Pages

DARATUMUMAB Full Profile All Oxygen saturation decreased Reports All Drugs Causing Oxygen saturation decreased DARATUMUMAB Demographics